论文部分内容阅读
目的分析霉酚酸酯在原发性肾病综合征中的应用效果。方法原发性肾病综合征患者80例,按照治疗方案分为对照组(40例)(口服强的松)和观察组(40例)(加用霉酚酸酯),比较两组治疗效果。结果观察组总缓解率达到92.5%(37/40),明显高于对照组72.5%(29/40);治疗后观察组患者血浆白蛋白、24 h尿蛋白水平较治疗前有明显改善,差异有统计学意义(P<0.05),对照组与治疗前比较改善不明显,差异无统计学意义(P>0.05);观察组治疗后血浆白蛋白、24 h尿蛋白水平优于对照组,差异有统计学意义(P<0.05)。结论在原发性肾病综合征治疗中,应用霉酚酸酯可有效提高治疗效果,改善患者血浆白蛋白、24 h尿蛋白水平,值得临床推广应用。
Objective To analyze the application effect of mycophenolate mofetil in primary nephrotic syndrome. Methods Eighty patients with primary nephrotic syndrome were divided into control group (40 cases) (oral prednisone) and observation group (40 cases) (plus mycophenolate mofetil) according to the treatment regimen. The therapeutic effect was compared between the two groups. Results The total remission rate in the observation group was 92.5% (37/40), significantly higher than that in the control group (72.5%, 29/40). After treatment, the levels of serum albumin and 24-h urine protein in the observation group were significantly improved, (P <0.05). There was no significant difference between the control group and before treatment (P> 0.05). The levels of serum albumin and 24-hour urine protein in the observation group were better than those in the control group There was statistical significance (P <0.05). Conclusion In the treatment of primary nephrotic syndrome, the application of mycophenolate mofetil can effectively improve the therapeutic effect and improve the level of serum albumin and 24 h urinary protein, which deserves clinical application.